Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
← catalyst calendarNCT04956640 · readout ≤ 254 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
540estimated
Sites
49
Countries
Australia, Canada, France +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-19 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Endometrial Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Biliary Tract Neoplasms
Interventions
- Drug: LY3537982 — also filed as Olomorasib
- Drug: Pembrolizumab — also filed as KEYTRUDA®
- Drug: Cetuximab — also filed as Erbitux
- Drug: Pemetrexed — also filed as LY231514, Alimta
- Drug: Cisplatin
- Drug: Carboplatin
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy
measured Cycle 1 (21 Days)
Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agents
measured Cycle 1 (21 Days)
Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumab
measured Estimated up to 2 years
To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximab
measured Estimated up to 2 years
To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation
measured Estimated up to 2 years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed